Jaypirca’s 80% Win Over Chemo Opens a First-Line CLL Fight With Three BTK Rivals
Jaypirca reaches first-line CLL on a win over chemo, and now has to take share from three covalent BTK inhibitors.
Jaypirca reaches first-line CLL on a win over chemo, and now has to take share from three covalent BTK inhibitors.
AbbVie now has to name a price for Juvmo into a benchmark that ICER set before the drug was even approved.
Three drugs now divide an ultra-rare disease by mechanism, route and age, and the newest competes on convenience and safety.
Median PFS doubled to 11.1 months against Inluriyo alone. The comparison payers will run is not in the package.
Lundbeck’s Fast Track makes three orexin programmes in two weeks. Plus a Duchenne filing with a January date, and a CHMP slip caused by a contract manufacturer.
The FDA granted De Novo authorization to OTTAVA, the first surgical robot with arms built into the operating table, cutting the footprint by up to half.
GSK’s Benlysta autoinjector gains FDA nod for pediatric lupus nephritis, enabling at-home treatment.